Licenses Of Seven Labs Revoked For Violations As Gujarat Cracks Down On Private Drug Testing Labs

Mumbai: In a decisive move to enforce stringent regulatory standards, the Gujarat Food and Drug Control Administration (FDCA) has revoked the licenses of seven private drug testing laboratories. This action followed a series of risk-based inspections targeting 19 labs across Ahmedabad, Baroda, and parts of South Gujarat.

The inspections, which aimed to ensure compliance with critical norms related to impurities, reference standards validation, calibration, testing tools, and instrumentation, revealed significant violations. Dr. H G Koshia, commissioner of the Gujarat FDCA, detailed the findings and the subsequent actions taken.

“We have 54 drug testing labs in Gujarat, out of which 19 were inspected. Serious violations were detected, following which stop testing orders and show cause notices were issued. Seven labs were put under strict scrutiny, and they were directed to resume their operations only after achieving full compliance,” stated Dr. Koshia.

He further explained that the crackdown underscores the FDCA’s commitment to maintaining high standards in drug testing processes, which are crucial for ensuring the safety and efficacy of pharmaceuticals. The revocation of licenses serves as a stern warning to other labs to adhere strictly to regulatory requirements.

This initiative is part of a broader strategy to enhance the reliability and integrity of drug testing procedures in the state, ultimately aiming to safeguard public health. The FDCA has reiterated its zero-tolerance policy towards non-compliance and vowed to continue rigorous inspections across all remaining laboratories.

The affected labs are now required to implement corrective measures and demonstrate adherence to prescribed norms before they can resume operations. This move is expected to prompt all drug testing facilities in Gujarat to reinforce their compliance frameworks and ensure adherence to the highest standards of practices.

Related Posts

  • Pharma
  • June 24, 2024
  • 79 views
PLI Scheme Review Committee Raises Concern Over Delays In Payments

New Delhi: A high-level government committee has raised concern over continued delays in payment to companies in the production-linked incentive (PLI) schemes, Business Standard has learnt. The committee has called…

  • Pharma
  • June 24, 2024
  • 89 views
Majority Of SLAs Did Not Submit NSQ Data In May: CDSCO

New Delhi: A large number of State Licensing Authorities (SLAs) seems to continue ignoring the Central Licensing Authority’s (CLA) direction to submit the monthly data on Not of Standard Quality (NSQ)…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

PLI Scheme Review Committee Raises Concern Over Delays In Payments

PLI Scheme Review Committee Raises Concern Over Delays In Payments

Majority Of SLAs Did Not Submit NSQ Data In May: CDSCO

Majority Of SLAs Did Not Submit NSQ Data In May: CDSCO

Gujarat Receives Rs. 18,155 Crore Investment As Part Of VGGS 2023: Dr H G Koshia

Gujarat Receives Rs. 18,155 Crore Investment As Part Of VGGS 2023: Dr H G Koshia

Sun Pharma Inks Non-Exclusive License Agreement With Takeda To Introduce Vonoprazan Tablets In India

Sun Pharma Inks Non-Exclusive License Agreement With Takeda To Introduce Vonoprazan Tablets In India

Look-Alike, Sounding Similar Drugs Likely To Face Strict Action

Look-Alike, Sounding Similar Drugs Likely To Face Strict Action

Centre Forms 5-Member Panel To Examine Manufacturing Of Nutraceuticals Within Drug Production Facility

Centre Forms 5-Member Panel To Examine Manufacturing Of Nutraceuticals Within Drug Production Facility